

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

June 28, 2023  
Date of Report (date of earliest event reported)

**LUMOS PHARMA, INC.**  
**(Exact name of registrant as specified in its charter)**

**Delaware**  
(State or other jurisdiction of incorporation or organization)

**001-35342**  
(Commission File Number)

**42-1491350**  
(I.R.S. Employer Identification No.)

**4200 Marathon Blvd., Suite 200**  
**Austin, Texas 78756**  
**(Address of Principal Executive Offices)**  
**(512) 215-2630**  
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	LUMO	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

On June 28, 2023, Lumos Pharma, Inc. issued a press release titled "Lumos Pharma Announces Departure of Chief Medical Officer."

A copy of the press release is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

---

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release, dated June 28, 2023, entitled " <a href="#">Lumos Pharma Announces Departure of Chief Medical Officer.</a> "

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 28, 2023

LUMOS PHARMA, INC.,  
a Delaware corporation

By: /s/ Richard J. Hawkins  
Richard J. Hawkins  
Its: Chief Executive Officer

## Lumos Pharma Announces Departure of Chief Medical Officer

AUSTIN, TX, June 28, 2023 – [Lumos Pharma, Inc.](https://www.lumos-pharma.com/) (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that Chief Medical Officer (CMO) Dr. David B. Karpf is departing the company to pursue other opportunities, effective June 29<sup>th</sup>. Dr. Pisit “Duke” Pitukcheewanont, Lumos Pharma’s Senior Vice President, Global Clinical Development and Medical Affairs, along with other members of our clinical team, will oversee all clinical activities and related functions until a CMO search is complete.

“We thank David for his many contributions to Lumos Pharma and know he will continue to advance the field of endocrinology in his work with Stanford University,” said Rick Hawkins, Chairman and Chief Executive Officer of Lumos Pharma. “Dr. Duke Pitukcheewanont, a pediatric endocrinologist with over 25 years’ experience and President of the Human Growth Foundation for 12 years, has been instrumental in the recruitment and conduct of our ongoing clinical trials. We are confident that Dr. Pitukcheewanont, along with our experienced clinical team, will continue to advance our programs effectively while we conduct a search for a permanent CMO replacement to execute the rollout of our planned Phase 3 development program.”

### **About Pediatric Growth Hormone Deficiency and LUM-201**

Pediatric Growth Hormone (GH) Deficiency is the consequence of inadequate secretion of growth hormone from the pituitary gland in children resulting in low GH in the body, insufficient production of downstream signaling molecules required for growth, and the subsequent lack of growth. LUM-201, also known as ibutamoren, is an orally administered investigational small molecule that promotes the secretion of GH from the pituitary gland and represents an opportunity for appropriately selected patients to avoid the daily or weekly injections involved with current or forthcoming therapies. LUM-201 has been observed to increase the amplitude of endogenous pulsatile GH secretion, which mimics the natural pattern of GH secretion.

### **About Lumos Pharma**

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in several Phase 2 clinical trials for the treatment of idiopathic Pediatric Growth Hormone Deficiency (iPGHD): the dose-finding OraGrowthH210 Trial; the PK/PD mechanistic OraGrowthH212 Trial; and a switch trial, the OraGrowthH213 Trial. If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit <https://lumos-pharma.com/>.

###

Investor & Media Contact:

Lisa Miller  
Lumos Pharma Investor Relations  
512-792-5454  
[ir@lumos-pharma.com](mailto:ir@lumos-pharma.com)